Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of th...
Uloženo v:
| Vydáno v: | The lancet oncology Ročník 19; číslo 11; s. 1480 - 1492 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
01.11.2018
Elsevier Limited |
| Témata: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.
In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505.
Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9–51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5–51·4) in the nivolumab group, and 18·6 months (7·6–49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2–not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3–not reached) in the nivolumab group, and 19·9 months (16·9–24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44–0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53–0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7–19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1–10·2) in the nivolumab group, and 2·9 months (2·8–3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35–0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44–0·64; p<0·0001). Treatment-related grade 3–4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.
The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Bristol-Myers Squibb. |
|---|---|
| AbstractList | Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.
In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505.
Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9–51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5–51·4) in the nivolumab group, and 18·6 months (7·6–49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2–not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3–not reached) in the nivolumab group, and 19·9 months (16·9–24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44–0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53–0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7–19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1–10·2) in the nivolumab group, and 2·9 months (2·8–3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35–0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44–0·64; p<0·0001). Treatment-related grade 3–4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.
The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Bristol-Myers Squibb. Summary Background Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. Methods In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505. Findings Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9–51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5–51·4) in the nivolumab group, and 18·6 months (7·6–49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2–not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3–not reached) in the nivolumab group, and 19·9 months (16·9–24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44–0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53–0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7–19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1–10·2) in the nivolumab group, and 2·9 months (2·8–3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35–0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44–0·64; p<0·0001). Treatment-related grade 3–4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis. Interpretation The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. Funding Bristol-Myers Squibb. Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.BACKGROUNDPreviously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505.METHODSIn this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505.Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.FINDINGSBetween July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.INTERPRETATIONThe results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.Bristol-Myers Squibb.FUNDINGBristol-Myers Squibb. Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAF mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505. Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis. The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. Bristol-Myers Squibb. SummaryBackgroundPreviously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. MethodsIn this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505. FindingsBetween July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9–51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5–51·4) in the nivolumab group, and 18·6 months (7·6–49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2–not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3–not reached) in the nivolumab group, and 19·9 months (16·9–24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44–0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53–0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7–19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1–10·2) in the nivolumab group, and 2·9 months (2·8–3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35–0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44–0·64; p<0·0001). Treatment-related grade 3–4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis. InterpretationThe results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. FundingBristol-Myers Squibb. |
| Author | Rutkowski, Piotr Ferrucci, Pier Francesco Hill, Andrew Lao, Christopher D Rizzo, Jasmine Dummer, Reinhard Cowey, Charles Lance Grob, Jean-Jacques Gonzalez, Rene Smylie, Michael Wolchok, Jedd D Hodi, Frank Stephen Hogg, David Jiang, Joel Schadendorf, Dirk Wagstaff, John Larkin, James Chiarion-Sileni, Vanna Marquez-Rodas, Ivan |
| Author_xml | – sequence: 1 givenname: Frank Stephen surname: Hodi fullname: Hodi, Frank Stephen email: stephen_hodi@dfci.harvard.edu organization: Dana-Farber Cancer Institute, Boston, MA, USA – sequence: 2 givenname: Vanna surname: Chiarion-Sileni fullname: Chiarion-Sileni, Vanna organization: Veneto Institute of Oncology IOV-IRCCS, Padua, Italy – sequence: 3 givenname: Rene surname: Gonzalez fullname: Gonzalez, Rene organization: University of Colorado Cancer Center, Denver, CO, USA – sequence: 4 givenname: Jean-Jacques surname: Grob fullname: Grob, Jean-Jacques organization: Aix-Marseille University and APHM Hospital CHU Timone, Marseille, France – sequence: 5 givenname: Piotr surname: Rutkowski fullname: Rutkowski, Piotr organization: Maria Skłodowska-Curie Institute – Oncology Centre, Warsaw, Poland – sequence: 6 givenname: Charles Lance surname: Cowey fullname: Cowey, Charles Lance organization: Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA – sequence: 7 givenname: Christopher D surname: Lao fullname: Lao, Christopher D organization: Department of Oncology, University of Michigan, Ann Arbor, MI, USA – sequence: 8 givenname: Dirk surname: Schadendorf fullname: Schadendorf, Dirk organization: Department of Dermatology, University of Essen, Essen, Germany – sequence: 9 givenname: John surname: Wagstaff fullname: Wagstaff, John organization: The College of Medicine, Swansea University, Swansea, UK – sequence: 10 givenname: Reinhard surname: Dummer fullname: Dummer, Reinhard organization: Department of Dermatology, Universitäts Spital, Zürich, Switzerland – sequence: 11 givenname: Pier Francesco surname: Ferrucci fullname: Ferrucci, Pier Francesco organization: European Institute of Oncology, Milan, Italy – sequence: 12 givenname: Michael surname: Smylie fullname: Smylie, Michael organization: Cross Cancer Institute, Edmonton, AB, Canada – sequence: 13 givenname: Andrew surname: Hill fullname: Hill, Andrew organization: Tasman Oncology Research, Southport, QLD, Australia – sequence: 14 givenname: David surname: Hogg fullname: Hogg, David organization: Princess Margaret Cancer Centre, Toronto, ON, Canada – sequence: 15 givenname: Ivan surname: Marquez-Rodas fullname: Marquez-Rodas, Ivan organization: General University Hospital Gregorio Marañón, Madrid, Spain – sequence: 16 givenname: Joel surname: Jiang fullname: Jiang, Joel organization: Bristol-Myers Squibb, Princeton, NJ, USA – sequence: 17 givenname: Jasmine surname: Rizzo fullname: Rizzo, Jasmine organization: Bristol-Myers Squibb, Princeton, NJ, USA – sequence: 18 givenname: James surname: Larkin fullname: Larkin, James organization: The Royal Marsden NHS Foundation Trust, London, UK – sequence: 19 givenname: Jedd D surname: Wolchok fullname: Wolchok, Jedd D organization: Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30361170$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkdtu1DAQhiNURA_wCCBL3GylBmwnTpwiQGjFSSpwAVxbs_ZEdevEi52stC_Ec-Js2kqshMpVEuebzzPzH2cHve8xy54y-oJRVr38zsqa5pyWYsHkaUFrSvPmQXaUjstclFIe7N5n5DA7jvGKUlYzKh5lhwUtKsZqepT9_mo33o0drMjajZHYtXW22337QPq7n-DS9WSDIf4Nzee2J2A20Gs0pEMHve-ALJaXqK-_wICEVvXpOSnzLUIgfhy07zAS3xIg3egGq7EfAp6RAL3xnY1ozsj6EiKSggzBgnucPWzBRXxy8zzJfn54_2P5Kb_49vHz8t1FrgXlQ64lW9V1AUCrphSmLdPAUBoj2mrVFjWWDYPCSK6FZiteCi605rIRUrKWm8YUJ9li9q6D_zViHFTqRqNLI6Efo-KMV02aRoqEPt9Dr_wY-tTdRNUVF03TJOrZDTWuOjRqHWwHYatuE0jAqxnQwccYsFXaDjBYnzYC1ilG1ZS32uWtpjAVk2qXt5r0Yq_69oL76t7OdZiWubEYVNQWp_xsQD0o4-29hjd7Bu1sbzW4a9xivNsFU5ErOksmB5M7wyR4_W_BfzTwBxop6dY |
| CitedBy_id | crossref_primary_10_1002_jac5_1531 crossref_primary_10_3389_fonc_2024_1366532 crossref_primary_10_1111_ajco_13385 crossref_primary_10_1172_JCI148549 crossref_primary_10_3390_pharmaceutics13060912 crossref_primary_10_1016_j_det_2022_07_007 crossref_primary_10_1200_EDBK_243071 crossref_primary_10_1002_cam4_3198 crossref_primary_10_1016_j_ad_2023_10_002 crossref_primary_10_1111_ddg_14726 crossref_primary_10_1111_jocd_16105 crossref_primary_10_1016_j_ejca_2023_04_010 crossref_primary_10_1080_21645515_2021_1971015 crossref_primary_10_1111_1346_8138_16820 crossref_primary_10_1111_ddg_14726_g crossref_primary_10_1016_j_canep_2021_101943 crossref_primary_10_1155_2019_1395138 crossref_primary_10_1016_j_it_2019_04_002 crossref_primary_10_1016_j_it_2021_09_007 crossref_primary_10_1371_journal_pone_0293469 crossref_primary_10_1007_s11912_022_01265_5 crossref_primary_10_1007_s11912_022_01243_x crossref_primary_10_3389_fimmu_2020_601497 crossref_primary_10_3390_cancers15051356 crossref_primary_10_1111_bcp_14338 crossref_primary_10_3390_jcm13061607 crossref_primary_10_1007_s00432_022_03939_w crossref_primary_10_1016_j_aohep_2022_100737 crossref_primary_10_2217_imt_2022_0140 crossref_primary_10_1016_j_jbc_2023_102902 crossref_primary_10_1002_cncr_33459 crossref_primary_10_1158_1078_0432_CCR_24_0553 crossref_primary_10_1080_14728222_2021_2010044 crossref_primary_10_1002_ijc_32934 crossref_primary_10_3390_cancers16020250 crossref_primary_10_1080_17512433_2019_1650641 crossref_primary_10_3390_cells10061450 crossref_primary_10_3390_ijms25168899 crossref_primary_10_1111_1346_8138_15957 crossref_primary_10_1186_s12967_023_04842_9 crossref_primary_10_1002_jso_27239 crossref_primary_10_1038_s41416_020_01071_5 crossref_primary_10_4103_jcrt_jcrt_1669_21 crossref_primary_10_3389_fonc_2022_851756 crossref_primary_10_1007_s40257_022_00681_4 crossref_primary_10_15212_AMM_2023_0037 crossref_primary_10_1021_jacs_0c07276 crossref_primary_10_1155_2022_4976032 crossref_primary_10_3390_biom9100548 crossref_primary_10_2174_0929867327666200422143847 crossref_primary_10_1111_bjd_20879 crossref_primary_10_3389_fimmu_2022_986214 crossref_primary_10_1111_cas_14015 crossref_primary_10_1111_ddg_14091_g crossref_primary_10_1038_s41467_021_21572_y crossref_primary_10_1016_j_tranon_2024_102224 crossref_primary_10_3390_ijms24021294 crossref_primary_10_3390_jcm10143047 crossref_primary_10_3390_ijms22063228 crossref_primary_10_3389_fimmu_2023_1161869 crossref_primary_10_3390_cancers12061414 crossref_primary_10_1016_j_eururo_2022_07_009 crossref_primary_10_3390_cancers12123828 crossref_primary_10_3389_fonc_2021_765608 crossref_primary_10_3390_cancers14092056 crossref_primary_10_3390_cancers13184620 crossref_primary_10_1111_dth_14193 crossref_primary_10_1177_2050313X211042215 crossref_primary_10_1016_j_ejca_2023_05_011 crossref_primary_10_1016_j_clindermatol_2023_10_012 crossref_primary_10_1186_s40425_019_0800_0 crossref_primary_10_1097_COC_0000000000000840 crossref_primary_10_1016_j_annder_2020_11_006 crossref_primary_10_3390_ijms24129855 crossref_primary_10_3390_cancers12061666 crossref_primary_10_1038_s41422_020_0277_x crossref_primary_10_1002_cam4_6671 crossref_primary_10_1038_s41392_020_0199_6 crossref_primary_10_2217_fon_2020_1193 crossref_primary_10_1016_j_ejca_2021_02_037 crossref_primary_10_1097_CPM_0000000000000373 crossref_primary_10_1080_14740338_2020_1757068 crossref_primary_10_1007_s11864_021_00827_2 crossref_primary_10_1016_j_annonc_2023_11_013 crossref_primary_10_1007_s00404_020_05589_0 crossref_primary_10_1073_pnas_2208900119 crossref_primary_10_1007_s00520_020_05710_8 crossref_primary_10_1016_j_semradonc_2019_12_008 crossref_primary_10_1016_j_ad_2023_01_016 crossref_primary_10_1007_s11912_019_0851_x crossref_primary_10_1016_j_bulcan_2020_06_011 crossref_primary_10_1016_j_ejca_2023_113287 crossref_primary_10_1007_s43152_023_00047_w crossref_primary_10_1111_ddg_14501 crossref_primary_10_1038_s41467_022_30861_z crossref_primary_10_1007_s12328_024_02050_6 crossref_primary_10_1080_1744666X_2022_2044796 crossref_primary_10_1038_s41591_021_01623_z crossref_primary_10_3389_fimmu_2023_1264327 crossref_primary_10_1007_s10147_019_01424_y crossref_primary_10_1002_ijc_32744 crossref_primary_10_1001_jamanetworkopen_2020_17675 crossref_primary_10_1007_s00066_019_01504_y crossref_primary_10_1007_s12072_025_10799_2 crossref_primary_10_1097_CMR_0000000000001023 crossref_primary_10_1111_jth_14774 crossref_primary_10_1038_s44276_024_00058_6 crossref_primary_10_1097_CAD_0000000000000798 crossref_primary_10_1016_S2468_1253_20_30014_5 crossref_primary_10_1080_14656566_2020_1729122 crossref_primary_10_1136_annrheumdis_2020_217139 crossref_primary_10_1158_1078_0432_CCR_19_1335 crossref_primary_10_1007_s12307_019_00232_2 crossref_primary_10_3390_md23070273 crossref_primary_10_4103_ATMR_ATMR_203_24 crossref_primary_10_1016_j_jhep_2025_03_033 crossref_primary_10_3390_ijms20174263 crossref_primary_10_1016_j_mpmed_2019_11_008 crossref_primary_10_1158_1078_0432_CCR_20_2415 crossref_primary_10_3390_ijms21228627 crossref_primary_10_1007_s12094_021_02723_5 crossref_primary_10_3389_fimmu_2020_00372 crossref_primary_10_1158_2326_6066_CIR_20_0586 crossref_primary_10_1016_j_yexmp_2019_104260 crossref_primary_10_3390_bios15050297 crossref_primary_10_1016_j_intimp_2022_108783 crossref_primary_10_1080_14737140_2020_1796646 crossref_primary_10_1055_s_0043_1776761 crossref_primary_10_1038_s41467_020_14632_2 crossref_primary_10_1007_s11596_023_2763_0 crossref_primary_10_3389_fonc_2021_639059 crossref_primary_10_1177_1758835920975353 crossref_primary_10_1111_cas_14621 crossref_primary_10_1038_s41573_021_00155_y crossref_primary_10_1111_1346_8138_17093 crossref_primary_10_1007_s11033_021_06660_y crossref_primary_10_1007_s11060_019_03363_0 crossref_primary_10_4103_ijmpo_ijmpo_199_20 crossref_primary_10_1002_JLB_5BT0420_585RR crossref_primary_10_3390_diagnostics12020480 crossref_primary_10_1111_ced_14965 crossref_primary_10_3322_caac_21560 crossref_primary_10_1158_1078_0432_CCR_19_3977 crossref_primary_10_3389_fonc_2020_571135 crossref_primary_10_1038_s41698_022_00330_3 crossref_primary_10_1007_s11912_023_01429_x crossref_primary_10_1080_1744666X_2024_2326626 crossref_primary_10_1039_D5TB01024A crossref_primary_10_1136_bcr_2018_228114 crossref_primary_10_1080_2162402X_2019_1684126 crossref_primary_10_1016_j_chembiol_2020_10_005 crossref_primary_10_1155_2021_8870334 crossref_primary_10_1016_j_jaad_2022_02_063 crossref_primary_10_1016_j_intimp_2022_109657 crossref_primary_10_1007_s00259_022_05780_2 crossref_primary_10_7759_cureus_23272 crossref_primary_10_1155_2019_1856594 crossref_primary_10_3390_ph14020089 crossref_primary_10_3389_fonc_2020_01677 crossref_primary_10_1097_CMR_0000000000000777 crossref_primary_10_3390_magnetochemistry11040033 crossref_primary_10_1186_s13073_020_00743_4 crossref_primary_10_1186_s40425_019_0828_1 crossref_primary_10_3390_jcm9010223 crossref_primary_10_1177_17588359211058393 crossref_primary_10_1186_s12967_024_05763_x crossref_primary_10_1016_j_ccell_2020_09_001 crossref_primary_10_1016_j_canep_2022_102265 crossref_primary_10_1016_j_suc_2019_09_009 crossref_primary_10_3390_cancers12082329 crossref_primary_10_1080_14737140_2024_2336106 crossref_primary_10_3390_biom11111648 crossref_primary_10_1177_1078155219877923 crossref_primary_10_1111_imj_70085 crossref_primary_10_1016_j_cps_2021_06_005 crossref_primary_10_1016_j_pmip_2023_100112 crossref_primary_10_1007_s00262_021_03133_w crossref_primary_10_1158_1078_0432_CCR_20_2452 crossref_primary_10_1016_j_immuni_2019_12_011 crossref_primary_10_1016_j_ymthe_2021_10_004 crossref_primary_10_1097_CCO_0000000000000802 crossref_primary_10_1016_j_cca_2020_05_017 crossref_primary_10_2217_imt_2020_0332 crossref_primary_10_3390_ijms22136932 crossref_primary_10_1002_cam4_2464 crossref_primary_10_1080_07347332_2020_1836547 crossref_primary_10_1038_s41591_022_02126_1 crossref_primary_10_3390_cancers14153779 crossref_primary_10_1016_j_ejca_2020_07_029 crossref_primary_10_1111_ajco_13177 crossref_primary_10_1080_13543784_2019_1598376 crossref_primary_10_3389_fimmu_2020_588552 crossref_primary_10_1097_CMR_0000000000000793 crossref_primary_10_2217_imt_2020_0320 crossref_primary_10_3390_cancers13122931 crossref_primary_10_1016_j_bbrc_2024_151011 crossref_primary_10_1016_j_canlet_2020_03_024 crossref_primary_10_7759_cureus_26359 crossref_primary_10_3389_fphar_2020_00040 crossref_primary_10_1016_j_pharmthera_2022_108301 crossref_primary_10_1186_s40425_019_0585_1 crossref_primary_10_1093_rheumatology_kez402 crossref_primary_10_1111_pcmr_12887 crossref_primary_10_1016_j_jaad_2020_09_054 crossref_primary_10_3389_fmed_2022_959289 crossref_primary_10_3389_fonc_2020_570080 crossref_primary_10_1200_JCO_19_00345 crossref_primary_10_3390_cancers15153966 crossref_primary_10_1186_s40425_019_0683_0 crossref_primary_10_1186_s40792_021_01345_x crossref_primary_10_1007_s10147_022_02215_8 crossref_primary_10_1080_21645515_2023_2207438 crossref_primary_10_3389_fimmu_2021_718621 crossref_primary_10_1245_s10434_022_11351_4 crossref_primary_10_1016_j_radonc_2023_110003 crossref_primary_10_1080_2162402X_2021_1873585 crossref_primary_10_1111_cns_13944 crossref_primary_10_7861_clinmed_2018_0440 crossref_primary_10_1186_s13046_024_03044_5 crossref_primary_10_1097_PPO_0000000000000437 crossref_primary_10_3390_cancers16112088 crossref_primary_10_1126_scitranslmed_adk0642 crossref_primary_10_1016_j_bbrc_2025_151536 crossref_primary_10_1007_s10585_023_10234_6 crossref_primary_10_1634_theoncologist_2019_0674 crossref_primary_10_3389_fimmu_2024_1329775 crossref_primary_10_3390_cancers11081213 crossref_primary_10_1016_j_it_2019_02_004 crossref_primary_10_1080_17474086_2019_1593135 crossref_primary_10_3390_ijms20061326 crossref_primary_10_3389_fonc_2022_962947 crossref_primary_10_1186_s12935_025_03800_3 crossref_primary_10_3390_molecules27123798 crossref_primary_10_1111_1346_8138_17002 crossref_primary_10_4330_wjc_v12_i11_584 crossref_primary_10_1186_s40425_019_0569_1 crossref_primary_10_1177_14604582231198021 crossref_primary_10_3390_medicina60071129 crossref_primary_10_1373_clinchem_2019_303644 crossref_primary_10_1093_annonc_mdz050 crossref_primary_10_1080_14737140_2020_1724097 crossref_primary_10_1158_2326_6066_CIR_20_0983 crossref_primary_10_1093_bjd_ljae470 crossref_primary_10_1245_s10434_019_08013_3 crossref_primary_10_3390_cancers13092043 crossref_primary_10_1080_14737140_2023_2160323 crossref_primary_10_1111_bph_70052 crossref_primary_10_3390_cancers12071826 crossref_primary_10_1007_s11912_019_0849_4 crossref_primary_10_3390_medicines6030074 crossref_primary_10_1155_2019_5269062 crossref_primary_10_2217_imt_2020_0002 crossref_primary_10_3390_cancers15092462 crossref_primary_10_3390_ijms231911943 crossref_primary_10_3389_fonc_2025_1614223 crossref_primary_10_3390_cancers14030682 crossref_primary_10_3390_ijms25126377 crossref_primary_10_1001_jamaophthalmol_2021_4786 crossref_primary_10_3322_caac_21727 crossref_primary_10_1158_1078_0432_CCR_20_0177 crossref_primary_10_1016_S1470_2045_19_30735_1 crossref_primary_10_3389_fonc_2022_1069963 crossref_primary_10_1016_j_ijpt_2025_100738 crossref_primary_10_1097_CMR_0000000000000945 crossref_primary_10_3389_fimmu_2023_1065767 crossref_primary_10_1007_s00262_020_02587_8 crossref_primary_10_2217_mmt_2019_0005 crossref_primary_10_3390_cancers13174362 crossref_primary_10_3390_ijms24010859 crossref_primary_10_1158_1078_0432_CCR_20_3449 crossref_primary_10_3390_jcm9020519 crossref_primary_10_1634_theoncologist_2018_0306 crossref_primary_10_3390_life11111277 crossref_primary_10_1016_j_intimp_2020_106628 crossref_primary_10_1007_s11912_019_0827_x crossref_primary_10_1097_CMR_0000000000000949 crossref_primary_10_1016_j_jtho_2025_05_019 crossref_primary_10_1177_10781552231177209 crossref_primary_10_1158_1078_0432_CCR_20_2345 crossref_primary_10_3390_cancers16173065 crossref_primary_10_31083_j_ceog5101007 crossref_primary_10_1158_2159_8290_CD_24_0066 crossref_primary_10_1016_j_ejca_2020_10_027 crossref_primary_10_1016_j_ejca_2024_115153 crossref_primary_10_1186_s12967_020_02285_0 crossref_primary_10_3390_cancers12051176 crossref_primary_10_1038_s41392_021_00827_6 crossref_primary_10_3390_ijms21030878 crossref_primary_10_1186_s12957_019_1669_6 crossref_primary_10_1002_cncr_34087 crossref_primary_10_1016_j_annonc_2022_06_008 crossref_primary_10_1177_2050313X211027737 crossref_primary_10_1158_1078_0432_CCR_23_0219 crossref_primary_10_3389_fonc_2022_877434 crossref_primary_10_1080_1750743X_2025_2473305 crossref_primary_10_2217_fon_2022_0615 crossref_primary_10_3390_ijms23020820 crossref_primary_10_3390_biomedicines10040822 crossref_primary_10_3390_biomedicines10071737 crossref_primary_10_1002_ijc_33000 crossref_primary_10_1016_j_ejca_2020_09_031 crossref_primary_10_3390_ijms23126388 crossref_primary_10_1158_2159_8290_CD_23_0352 crossref_primary_10_1001_jamanetworkopen_2021_39573 crossref_primary_10_1007_s11912_019_0847_6 crossref_primary_10_2217_imt_2018_0208 crossref_primary_10_36425_rehab79387 crossref_primary_10_3390_cancers16101825 crossref_primary_10_1186_s13046_019_1259_z crossref_primary_10_1155_2020_4392562 crossref_primary_10_1177_17588359231186027 crossref_primary_10_1016_j_ejca_2019_08_032 crossref_primary_10_1016_j_ejca_2018_12_015 crossref_primary_10_3389_fmolb_2024_1403021 crossref_primary_10_3389_fimmu_2020_594271 crossref_primary_10_3390_cancers17091595 crossref_primary_10_1111_jdv_17373 crossref_primary_10_1016_j_ebiom_2022_104235 crossref_primary_10_3390_cancers12020482 crossref_primary_10_3390_jcm9020318 crossref_primary_10_1159_000517344 crossref_primary_10_1016_j_imbio_2024_152844 crossref_primary_10_1159_000500902 crossref_primary_10_1016_j_prp_2022_154241 crossref_primary_10_1007_s00432_024_05981_2 crossref_primary_10_3390_nano11030661 crossref_primary_10_1016_j_ejca_2020_11_027 crossref_primary_10_1038_s41590_023_01569_z crossref_primary_10_1186_s12885_023_11080_1 crossref_primary_10_1016_j_wneu_2020_08_124 crossref_primary_10_1186_s12964_020_00599_6 crossref_primary_10_3748_wjg_v27_i32_5376 crossref_primary_10_1186_s13045_023_01445_1 crossref_primary_10_1097_CMR_0000000000000739 crossref_primary_10_3390_cancers14225543 crossref_primary_10_3390_cancers16142559 crossref_primary_10_1158_0008_5472_CAN_20_3182 crossref_primary_10_1016_j_soncn_2019_08_011 crossref_primary_10_3390_ijms22136741 crossref_primary_10_1097_PPO_0000000000000712 crossref_primary_10_3389_fsurg_2021_771160 crossref_primary_10_1096_fj_201902024 crossref_primary_10_3390_molecules26040785 crossref_primary_10_1089_mab_2021_0004 crossref_primary_10_1007_s00259_022_05986_4 crossref_primary_10_3389_fimmu_2021_765644 crossref_primary_10_1038_s41598_021_01627_2 crossref_primary_10_1080_13543784_2019_1654995 crossref_primary_10_1016_j_biopha_2019_109625 crossref_primary_10_1038_s41571_019_0317_y crossref_primary_10_1007_s00415_024_12660_2 crossref_primary_10_1111_vco_12829 crossref_primary_10_1002_mef2_70009 crossref_primary_10_1016_j_ejso_2020_08_025 crossref_primary_10_1016_j_cca_2021_04_010 crossref_primary_10_1002_iju5_12101 crossref_primary_10_1016_j_bjoms_2020_11_008 crossref_primary_10_3390_life15091447 crossref_primary_10_3390_diagnostics15121560 crossref_primary_10_1016_j_molmed_2024_09_009 crossref_primary_10_3389_fonc_2021_645069 crossref_primary_10_1016_j_intimp_2024_111707 crossref_primary_10_4049_jimmunol_2100700 crossref_primary_10_1016_j_gastrohep_2023_10_009 crossref_primary_10_1177_1758835920940927 crossref_primary_10_3389_fonc_2021_766500 crossref_primary_10_3390_ijms24021362 crossref_primary_10_1016_j_annonc_2020_05_031 crossref_primary_10_3390_cancers13164138 crossref_primary_10_1038_s41572_020_0160_6 crossref_primary_10_3390_cancers12113486 crossref_primary_10_3390_biomedicines10102528 crossref_primary_10_1007_s00281_022_00980_2 crossref_primary_10_1016_j_annonc_2023_10_125 crossref_primary_10_1002_cncr_32522 crossref_primary_10_1007_s00105_019_04514_0 crossref_primary_10_1080_13543784_2022_2027366 crossref_primary_10_3389_fonc_2020_592609 crossref_primary_10_1186_s40164_019_0150_0 crossref_primary_10_3390_biom12091226 crossref_primary_10_1016_j_jdin_2021_09_002 crossref_primary_10_3390_jcm8101596 crossref_primary_10_3389_fonc_2021_710585 crossref_primary_10_1007_s12325_023_02555_5 crossref_primary_10_3389_fgene_2022_988821 crossref_primary_10_3390_cancers14061575 crossref_primary_10_3390_cancers12051101 crossref_primary_10_3389_fimmu_2022_860421 crossref_primary_10_1007_s40264_018_0778_4 crossref_primary_10_1080_14712598_2022_2038132 crossref_primary_10_36290_xon_2020_068 crossref_primary_10_1111_imj_14919 crossref_primary_10_1097_CJI_0000000000000334 crossref_primary_10_3389_fimmu_2023_1121285 crossref_primary_10_1158_2159_8290_CD_19_1510 crossref_primary_10_1186_s12885_021_08018_w crossref_primary_10_1016_j_annonc_2020_07_004 crossref_primary_10_2147_CMAR_S249540 crossref_primary_10_1016_j_ejca_2023_113501 crossref_primary_10_1158_2159_8290_CD_20_0522 crossref_primary_10_1097_CJI_0000000000000339 crossref_primary_10_1016_j_ejca_2021_03_012 crossref_primary_10_1016_j_phrs_2021_105997 crossref_primary_10_1177_10781552241265058 crossref_primary_10_3390_cancers17172805 crossref_primary_10_3389_fimmu_2020_00604 crossref_primary_10_3389_fimmu_2023_1324618 crossref_primary_10_3892_mco_2022_2537 crossref_primary_10_1088_1361_6560_abc3fc crossref_primary_10_3390_ijms252413558 crossref_primary_10_3389_fimmu_2023_1225140 crossref_primary_10_1016_j_ejca_2021_04_045 crossref_primary_10_1186_s12964_022_00854_y crossref_primary_10_3390_jpm13111616 crossref_primary_10_1016_j_jaccao_2020_08_007 crossref_primary_10_1007_s40257_019_00475_1 crossref_primary_10_3390_ijms26146778 crossref_primary_10_1016_j_ctrv_2021_102280 crossref_primary_10_3389_fonc_2024_1322116 crossref_primary_10_1073_pnas_2102849118 crossref_primary_10_1080_0284186X_2020_1818823 crossref_primary_10_3389_fimmu_2024_1520441 crossref_primary_10_1016_j_intimp_2024_111989 crossref_primary_10_1007_s00520_021_06543_9 crossref_primary_10_3389_fimmu_2024_1391524 crossref_primary_10_1111_jdv_16678 crossref_primary_10_1016_j_ejca_2021_04_032 crossref_primary_10_12998_wjcc_v12_i8_1510 crossref_primary_10_1007_s11864_019_0634_5 crossref_primary_10_1056_NEJMoa1910836 crossref_primary_10_1111_1346_8138_16518 crossref_primary_10_1111_ijd_17379 crossref_primary_10_1001_jamanetworkopen_2020_28627 crossref_primary_10_1016_S1470_2045_19_30274_8 crossref_primary_10_1016_j_chembiol_2023_10_010 crossref_primary_10_1080_2162402X_2022_2116845 crossref_primary_10_1177_0145561320940847 crossref_primary_10_1158_0008_5472_CAN_20_2000 crossref_primary_10_1186_s40425_019_0645_6 crossref_primary_10_2217_imt_2019_0164 crossref_primary_10_1016_j_ejca_2021_04_021 crossref_primary_10_1002_eji_202048747 crossref_primary_10_3390_cancers14051337 crossref_primary_10_1016_j_ad_2020_07_003 crossref_primary_10_1016_j_xcrm_2025_102183 crossref_primary_10_1186_s12885_021_08908_z crossref_primary_10_1038_s41598_025_05930_0 crossref_primary_10_1186_s12967_025_06467_6 crossref_primary_10_3390_biomedicines10112977 crossref_primary_10_1007_s12032_025_02691_8 crossref_primary_10_1097_CJI_0000000000000375 crossref_primary_10_1188_19_CJON_355_358 crossref_primary_10_1084_jem_20221333 crossref_primary_10_3389_fonc_2022_980181 crossref_primary_10_1111_1346_8138_15408 crossref_primary_10_1111_cns_13380 crossref_primary_10_3389_fonc_2022_934093 crossref_primary_10_1016_j_jaad_2020_03_131 crossref_primary_10_1080_08923973_2021_1924195 crossref_primary_10_3390_immuno2020020 crossref_primary_10_1002_cncr_32542 crossref_primary_10_1016_S1470_2045_19_30483_8 crossref_primary_10_1007_s12288_021_01473_2 crossref_primary_10_1016_j_ctrv_2022_102373 crossref_primary_10_3389_fmed_2019_00174 crossref_primary_10_1007_s11912_023_01402_8 crossref_primary_10_1111_ajd_13498 crossref_primary_10_1177_17588359221131521 crossref_primary_10_1111_pcmr_12944 crossref_primary_10_1038_s41591_019_0482_7 crossref_primary_10_1080_2162402X_2021_1992880 crossref_primary_10_1016_j_critrevonc_2024_104276 crossref_primary_10_1016_j_jgo_2019_12_012 crossref_primary_10_1016_j_bbcan_2019_188314 crossref_primary_10_3390_genes15020162 crossref_primary_10_1016_j_wneu_2023_09_042 crossref_primary_10_1186_s12885_025_13611_4 crossref_primary_10_1016_j_ejca_2022_02_008 crossref_primary_10_1016_j_heliyon_2024_e35655 crossref_primary_10_3390_cancers11091342 crossref_primary_10_1016_j_drup_2019_07_004 crossref_primary_10_3390_ijms23031119 crossref_primary_10_3390_cancers16233929 crossref_primary_10_3389_fimmu_2020_01721 crossref_primary_10_3390_cancers13215301 crossref_primary_10_3390_cancers13215550 crossref_primary_10_3390_cancers16233920 crossref_primary_10_1016_j_ejcskn_2025_100731 crossref_primary_10_3390_cells12172147 crossref_primary_10_3390_genes14051021 crossref_primary_10_1007_s43441_020_00126_2 crossref_primary_10_3390_ijms21061930 crossref_primary_10_1038_s41392_022_01136_2 crossref_primary_10_1038_s42003_021_02972_8 crossref_primary_10_1016_j_canlet_2022_215738 crossref_primary_10_1080_17843286_2022_2114684 crossref_primary_10_3233_KCA_190054 crossref_primary_10_3389_fphar_2022_854967 crossref_primary_10_1016_j_ejca_2021_08_048 crossref_primary_10_1111_liv_14489 crossref_primary_10_3390_jcm10215124 crossref_primary_10_1016_j_ctrv_2019_02_001 crossref_primary_10_1186_s12957_022_02732_w crossref_primary_10_1177_17588359251324035 crossref_primary_10_1007_s12032_023_02104_8 crossref_primary_10_1186_s12967_019_1892_5 crossref_primary_10_1016_j_ejca_2019_11_015 crossref_primary_10_3390_cancers14071669 crossref_primary_10_1158_1078_0432_CCR_22_3468 crossref_primary_10_1111_bcp_14433 crossref_primary_10_3390_ijms20246337 crossref_primary_10_1007_s40265_020_01270_7 crossref_primary_10_1177_17588359251349321 crossref_primary_10_1002_JLB_MR0618_241RR crossref_primary_10_1016_j_intimp_2021_107443 crossref_primary_10_3390_biomedicines10030655 crossref_primary_10_1007_s11060_020_03481_0 crossref_primary_10_1007_s12094_021_02659_w crossref_primary_10_1038_s41591_020_01211_7 crossref_primary_10_1080_01676830_2020_1818265 crossref_primary_10_1080_2162402X_2022_2096535 crossref_primary_10_3389_fphar_2020_00557 crossref_primary_10_3390_cancers13133310 crossref_primary_10_1002_ejhf_2289 crossref_primary_10_1097_MD_0000000000019367 crossref_primary_10_1093_annonc_mdz411 crossref_primary_10_1093_jnci_djac019 crossref_primary_10_1245_s10434_019_08099_9 crossref_primary_10_3389_fmed_2019_00140 crossref_primary_10_3390_cancers12051319 crossref_primary_10_3389_fonc_2024_1484716 crossref_primary_10_1038_s41571_019_0266_5 crossref_primary_10_1097_MD_0000000000029390 crossref_primary_10_1080_14712598_2022_2116273 crossref_primary_10_3390_ijerph19042331 crossref_primary_10_1056_NEJMoa2109970 crossref_primary_10_1186_s13046_019_1426_2 crossref_primary_10_1186_s40644_020_00322_1 crossref_primary_10_1007_s00280_019_03926_y crossref_primary_10_1016_j_soc_2020_02_010 crossref_primary_10_3390_ijms23010488 crossref_primary_10_3389_fphar_2024_1383212 crossref_primary_10_1016_j_survophthal_2021_01_001 crossref_primary_10_1186_s13045_020_00922_1 crossref_primary_10_1186_s13046_022_02584_y crossref_primary_10_1371_journal_pone_0301223 crossref_primary_10_1227_neu_0000000000002127 crossref_primary_10_1158_1078_0432_CCR_20_0776 crossref_primary_10_1016_j_radmp_2025_02_001 crossref_primary_10_1016_S0140_6736_20_30417_7 crossref_primary_10_3389_fonc_2021_625872 crossref_primary_10_3390_cancers13184520 crossref_primary_10_3390_pharmaceutics16060732 crossref_primary_10_3389_fonc_2021_645245 crossref_primary_10_1002_hep_32215 crossref_primary_10_1016_j_smim_2020_101430 crossref_primary_10_1177_1078155219858657 crossref_primary_10_3389_fmed_2020_00090 crossref_primary_10_1016_j_preteyeres_2021_100971 crossref_primary_10_3389_fcell_2022_813043 crossref_primary_10_1111_ajco_13233 crossref_primary_10_1016_j_smim_2020_101414 crossref_primary_10_1111_ddg_15727 crossref_primary_10_1186_s12885_025_14805_6 crossref_primary_10_1007_s12020_020_02355_9 crossref_primary_10_3389_fimmu_2021_691134 crossref_primary_10_1007_s40259_020_00428_9 crossref_primary_10_1007_s40290_020_00326_z crossref_primary_10_1097_COH_0000000000000863 crossref_primary_10_1177_1758835920929583 crossref_primary_10_1007_s11912_022_01257_5 crossref_primary_10_1016_j_ctrv_2025_102886 crossref_primary_10_1080_2162402X_2021_1956142 crossref_primary_10_1097_CMR_0000000000000885 crossref_primary_10_1097_CMR_0000000000000882 crossref_primary_10_1186_s12967_025_06768_w crossref_primary_10_1111_jcmm_15991 crossref_primary_10_3390_jcm14186452 crossref_primary_10_3389_fonc_2021_667650 crossref_primary_10_3389_fimmu_2020_00490 crossref_primary_10_1016_j_ejca_2024_114305 crossref_primary_10_1158_0008_5472_CAN_20_0434 crossref_primary_10_1111_1759_7714_15433 crossref_primary_10_1097_CMR_0000000000000878 crossref_primary_10_1111_jdv_19467 crossref_primary_10_1097_CMR_0000000000000633 crossref_primary_10_1111_cei_13502 crossref_primary_10_1016_j_jbspin_2021_105168 crossref_primary_10_1080_2162402X_2019_1593806 crossref_primary_10_1177_1078155219862341 crossref_primary_10_1080_21645515_2021_1889449 crossref_primary_10_3390_cancers12010125 crossref_primary_10_1007_s00761_021_00903_0 crossref_primary_10_1038_s44276_024_00057_7 crossref_primary_10_3389_fendo_2023_1295865 crossref_primary_10_3389_fonc_2020_00476 crossref_primary_10_3390_medicina60060884 crossref_primary_10_1093_cei_uxac006 crossref_primary_10_3390_cancers14194796 crossref_primary_10_3389_fonc_2022_865656 crossref_primary_10_3389_fimmu_2023_1107848 crossref_primary_10_1080_07357907_2020_1714053 crossref_primary_10_3390_cancers13246217 crossref_primary_10_1016_j_semcancer_2019_08_024 crossref_primary_10_1038_s41392_020_00418_x crossref_primary_10_3389_fonc_2019_00937 crossref_primary_10_1080_17474086_2019_1596793 crossref_primary_10_1038_s41467_020_19810_w crossref_primary_10_1007_s13304_025_02367_y crossref_primary_10_1007_s10147_020_01618_9 crossref_primary_10_1016_j_ymthe_2022_05_008 crossref_primary_10_2217_imt_2021_0031 crossref_primary_10_1038_s41571_023_00782_x crossref_primary_10_1016_j_ygyno_2024_06_002 crossref_primary_10_1097_JS9_0000000000000368 crossref_primary_10_2147_CEOR_S238725 crossref_primary_10_1007_s00262_020_02579_8 crossref_primary_10_1093_jnci_djaa057 crossref_primary_10_1016_j_coms_2021_11_010 crossref_primary_10_1002_cam4_4593 crossref_primary_10_1002_ccr3_3424 crossref_primary_10_1016_j_adengl_2020_07_005 crossref_primary_10_1093_ajcp_aqae056 crossref_primary_10_1093_oncolo_oyaf173 crossref_primary_10_1177_2515135519862234 crossref_primary_10_3389_fonc_2023_1118301 crossref_primary_10_3390_cancers14194576 crossref_primary_10_1186_s12967_020_02588_2 crossref_primary_10_1111_ddg_14501_g crossref_primary_10_1080_14712598_2020_1693540 crossref_primary_10_2217_imt_2020_0217 crossref_primary_10_2217_fon_2021_1536 crossref_primary_10_1097_CMR_0000000000000683 crossref_primary_10_1186_s12979_024_00463_y crossref_primary_10_3390_cancers12040832 crossref_primary_10_1097_CMR_0000000000000680 crossref_primary_10_1177_09622802251327686 crossref_primary_10_3389_fonc_2025_1549237 crossref_primary_10_1073_pnas_2200708119 crossref_primary_10_3390_ijms22041958 crossref_primary_10_1186_s12951_023_01966_4 crossref_primary_10_3389_fimmu_2021_740890 crossref_primary_10_1016_j_semcancer_2019_08_001 crossref_primary_10_1016_j_critrevonc_2025_104763 crossref_primary_10_1038_s41416_021_01310_3 crossref_primary_10_1016_j_critrevonc_2025_104768 crossref_primary_10_1016_j_gastre_2023_10_003 crossref_primary_10_3389_fonc_2021_562315 crossref_primary_10_1007_s40259_020_00450_x crossref_primary_10_2217_mmt_2023_0006 crossref_primary_10_3390_cancers15041074 crossref_primary_10_1186_s40644_022_00449_3 crossref_primary_10_1016_j_jconrel_2022_07_035 crossref_primary_10_1038_s41571_023_00760_3 crossref_primary_10_2174_1381612826666200130091318 crossref_primary_10_1016_j_rdc_2020_04_003 crossref_primary_10_4240_wjgs_v16_i8_2374 crossref_primary_10_2217_imt_2023_0001 crossref_primary_10_1093_oncolo_oyaf144 crossref_primary_10_3390_biom10101447 crossref_primary_10_1080_14712598_2023_2215922 crossref_primary_10_2217_imt_2020_0202 crossref_primary_10_1007_s44178_024_00090_z crossref_primary_10_1016_j_ejca_2024_114120 crossref_primary_10_3390_cancers15071989 crossref_primary_10_1016_j_advms_2020_05_005 crossref_primary_10_2217_imt_2018_0168 crossref_primary_10_3390_cancers15010284 crossref_primary_10_18502_jovr_v17i3_11579 crossref_primary_10_3390_cancers14163878 crossref_primary_10_1016_j_radonc_2021_06_037 crossref_primary_10_1016_S1470_2045_18_30753_8 crossref_primary_10_1016_j_ophtha_2019_09_018 crossref_primary_10_3390_cancers12092429 crossref_primary_10_1038_s41416_020_0738_5 crossref_primary_10_1177_11795549221099869 crossref_primary_10_3390_cancers15010031 crossref_primary_10_1080_0284186X_2019_1670862 crossref_primary_10_1007_s11060_019_03355_0 crossref_primary_10_3390_cancers12071752 crossref_primary_10_1038_s41416_019_0724_y crossref_primary_10_3390_antibiotics9110740 crossref_primary_10_1016_j_ejca_2024_114148 crossref_primary_10_1186_s40545_023_00611_7 crossref_primary_10_3390_biomedicines12091979 crossref_primary_10_3390_biom10071061 crossref_primary_10_1097_CMR_0000000000000693 crossref_primary_10_1007_s11864_019_0607_8 crossref_primary_10_1038_s41467_024_52923_0 crossref_primary_10_3390_cancers16010131 crossref_primary_10_3390_cancers14092300 crossref_primary_10_1245_s10434_020_08566_8 crossref_primary_10_3390_ijms21238984 crossref_primary_10_1111_1346_8138_17147 crossref_primary_10_3390_cancers14204975 crossref_primary_10_1111_jdv_16128 crossref_primary_10_3390_cancers13174462 crossref_primary_10_1080_17460441_2021_1942834 crossref_primary_10_1002_cam4_2661 crossref_primary_10_3389_fonc_2020_00091 crossref_primary_10_1016_j_canlet_2025_218038 crossref_primary_10_1016_j_ctro_2022_100573 crossref_primary_10_1007_s40261_025_01456_5 crossref_primary_10_1016_j_wneu_2021_10_179 crossref_primary_10_1016_j_clnesp_2025_03_026 crossref_primary_10_1002_ehf2_12551 crossref_primary_10_1007_s15004_019_6708_5 crossref_primary_10_1177_20406223221099334 crossref_primary_10_1016_j_addr_2019_06_005 crossref_primary_10_3390_genes13101757 crossref_primary_10_1007_s40257_021_00593_9 crossref_primary_10_1111_jdv_16358 crossref_primary_10_1002_cpt_1956 crossref_primary_10_1002_cti2_1145 crossref_primary_10_1016_j_jlb_2025_100295 crossref_primary_10_1186_s12957_020_01933_5 crossref_primary_10_3389_fonc_2019_01033 crossref_primary_10_1093_jjco_hyad144 crossref_primary_10_1155_2020_4196178 crossref_primary_10_1016_j_radonc_2021_08_021 crossref_primary_10_1158_1078_0432_CCR_18_1550 crossref_primary_10_1016_j_annonc_2024_02_005 crossref_primary_10_1016_j_intimp_2023_109881 crossref_primary_10_3389_fonc_2021_604227 crossref_primary_10_3389_fonc_2021_672172 crossref_primary_10_1007_s00108_024_01742_y crossref_primary_10_1038_s41591_025_03699_3 crossref_primary_10_1016_j_ejso_2023_107249 crossref_primary_10_1007_s10143_022_01839_8 crossref_primary_10_3390_cancers13050989 crossref_primary_10_1007_s00262_024_03736_z crossref_primary_10_1007_s11136_023_03427_9 crossref_primary_10_1016_j_ejca_2020_02_021 crossref_primary_10_1158_2326_6066_CIR_19_0866 crossref_primary_10_1016_j_heliyon_2023_e23919 crossref_primary_10_3389_fonc_2021_640314 crossref_primary_10_1007_s11523_020_00767_1 crossref_primary_10_1152_ajpgi_00022_2024 crossref_primary_10_3390_ijms241512174 crossref_primary_10_1016_j_ejca_2021_12_033 crossref_primary_10_12998_wjcc_v9_i11_2641 crossref_primary_10_1097_CJI_0000000000000291 crossref_primary_10_3389_fonc_2021_662392 crossref_primary_10_3390_cancers15092561 crossref_primary_10_1007_s00105_019_04496_z crossref_primary_10_1097_CJI_0000000000000293 crossref_primary_10_1016_j_tips_2019_07_001 crossref_primary_10_1186_s40164_019_0138_9 crossref_primary_10_1016_j_annonc_2022_01_076 crossref_primary_10_1111_imr_13248 crossref_primary_10_2174_0109298673283943240227104122 crossref_primary_10_1038_s41598_023_44028_3 crossref_primary_10_1126_science_aay4014 crossref_primary_10_1002_cam4_2625 crossref_primary_10_1002_med_21632 crossref_primary_10_1097_CMR_0000000000000604 crossref_primary_10_3389_fimmu_2019_01242 crossref_primary_10_1002_ijc_34218 crossref_primary_10_3390_ijms21072367 crossref_primary_10_1158_1078_0432_CCR_24_0900 crossref_primary_10_1200_JCO_18_01998 crossref_primary_10_3390_biomedicines11051496 crossref_primary_10_1097_MD_0000000000016653 crossref_primary_10_3390_cancers11081048 crossref_primary_10_3390_jcm12082785 crossref_primary_10_1007_s11912_020_0886_z crossref_primary_10_1002_jso_26607 crossref_primary_10_1007_s12094_021_02598_6 crossref_primary_10_1016_j_ctrv_2021_102335 crossref_primary_10_1111_1346_8138_15151 crossref_primary_10_1007_s12032_025_02694_5 crossref_primary_10_1111_ddg_14091 crossref_primary_10_3389_fphar_2022_883655 crossref_primary_10_1016_j_jdcr_2025_03_016 crossref_primary_10_1038_s41467_022_27960_2 crossref_primary_10_1038_s41416_021_01413_x crossref_primary_10_2217_fon_2022_0969 crossref_primary_10_1016_j_wneu_2022_02_125 crossref_primary_10_1634_theoncologist_2018_0876 crossref_primary_10_1111_imm_13323 crossref_primary_10_3389_fimmu_2022_1011040 crossref_primary_10_1007_s13233_024_00322_1 crossref_primary_10_3389_fimmu_2020_622442 crossref_primary_10_3390_cancers13040743 crossref_primary_10_1186_s12916_021_01955_0 crossref_primary_10_2217_imt_2020_0152 crossref_primary_10_3390_ijms25052984 crossref_primary_10_1016_j_clnesp_2025_02_004 crossref_primary_10_1016_j_jconrel_2023_12_007 crossref_primary_10_3389_fimmu_2019_02354 crossref_primary_10_1038_s41591_022_02084_8 crossref_primary_10_1126_scitranslmed_add1868 crossref_primary_10_2174_0929867329666220819115849 crossref_primary_10_3389_fonc_2020_00261 crossref_primary_10_1016_j_smim_2023_101754 crossref_primary_10_3389_fonc_2023_1256800 crossref_primary_10_1007_s00393_020_00876_2 crossref_primary_10_3390_biomedicines10102656 crossref_primary_10_1016_j_canrad_2022_04_005 crossref_primary_10_3390_cancers13061430 crossref_primary_10_1093_ehjcr_ytz182 crossref_primary_10_2147_CMAR_S286453 crossref_primary_10_1007_s12609_019_00333_3 crossref_primary_10_4103_UROS_UROS_11_19 crossref_primary_10_1007_s00262_019_02346_4 crossref_primary_10_1371_journal_pone_0248097 crossref_primary_10_1200_JCO_19_02133 crossref_primary_10_3389_fmolb_2019_00160 crossref_primary_10_1093_annonc_mdz182 crossref_primary_10_3389_fonc_2021_811434 crossref_primary_10_1016_j_rhum_2021_10_564 crossref_primary_10_1097_MD_0000000000037587 crossref_primary_10_1016_j_chembiol_2023_06_016 crossref_primary_10_1177_0272989X251319338 crossref_primary_10_1093_clinchem_hvaa321 crossref_primary_10_3390_biomedicines10102424 crossref_primary_10_1158_1078_0432_CCR_24_2681 crossref_primary_10_3390_vaccines8040632 crossref_primary_10_1016_S1470_2045_23_00411_4 crossref_primary_10_1038_s41598_025_87553_z crossref_primary_10_1097_RCT_0000000000001315 crossref_primary_10_1007_s00262_019_02353_5 crossref_primary_10_1016_S1470_2045_19_30388_2 crossref_primary_10_1007_s40258_020_00620_6 crossref_primary_10_1371_journal_pone_0252751 crossref_primary_10_1080_0284186X_2020_1712473 crossref_primary_10_1158_2326_6066_CIR_24_0387 crossref_primary_10_1002_ijc_35103 crossref_primary_10_1080_14737140_2023_2262764 crossref_primary_10_3390_cancers15051404 crossref_primary_10_3390_ijms21114055 crossref_primary_10_1111_1346_8138_16669 crossref_primary_10_3390_ijms252312821 crossref_primary_10_3390_cancers12030540 crossref_primary_10_1016_j_heliyon_2024_e38888 crossref_primary_10_1016_j_ijrobp_2022_03_030 crossref_primary_10_3390_biomedicines10030717 crossref_primary_10_1016_j_jaad_2021_12_062 crossref_primary_10_1016_j_ejca_2022_04_018 crossref_primary_10_1016_j_intimp_2024_111823 crossref_primary_10_13105_wjma_v8_i3_190 crossref_primary_10_1177_1724600819883658 crossref_primary_10_3390_cancers12123754 crossref_primary_10_1093_intimm_dxad035 crossref_primary_10_1186_s12943_020_01290_7 crossref_primary_10_1016_j_canlet_2019_10_013 crossref_primary_10_1007_s00259_020_05068_3 crossref_primary_10_1186_s40425_019_0659_0 crossref_primary_10_1016_j_intimp_2024_112903 crossref_primary_10_1051_e3sconf_202018503009 crossref_primary_10_1097_IOP_0000000000002407 crossref_primary_10_1093_neuonc_noz171 crossref_primary_10_3389_fimmu_2020_595655 crossref_primary_10_3389_fonc_2020_00905 crossref_primary_10_1016_j_annonc_2020_10_602 crossref_primary_10_1007_s00292_020_00776_x crossref_primary_10_1002_jcp_30645 crossref_primary_10_7759_cureus_68542 crossref_primary_10_1016_j_ejphar_2024_176913 crossref_primary_10_1080_14737159_2022_2049243 crossref_primary_10_1016_S1470_2045_19_30151_2 crossref_primary_10_1038_s41598_020_69330_2 crossref_primary_10_1016_j_ctrv_2022_102463 crossref_primary_10_3390_ijms21155186 crossref_primary_10_1007_s00259_020_04826_7 crossref_primary_10_1007_s00432_023_05199_8 crossref_primary_10_1016_j_phrs_2021_105643 crossref_primary_10_1016_S0151_9638_18_31288_2 crossref_primary_10_1177_1758835920937612 crossref_primary_10_1038_s41571_025_01000_6 crossref_primary_10_1002_cam4_2614 crossref_primary_10_1038_s41598_023_40980_2 crossref_primary_10_3389_fonc_2024_1366261 crossref_primary_10_1016_j_it_2018_12_003 crossref_primary_10_3389_fmed_2021_769368 crossref_primary_10_1007_s10147_021_01872_5 crossref_primary_10_1080_14737140_2020_1711737 crossref_primary_10_3390_cancers14174066 crossref_primary_10_3390_cancers15123109 crossref_primary_10_1007_s00259_020_04815_w crossref_primary_10_1007_s00761_019_00670_z crossref_primary_10_1080_14737167_2021_1845144 crossref_primary_10_3390_cancers14174069 crossref_primary_10_3390_cancers16030559 crossref_primary_10_1111_jdv_18501 crossref_primary_10_3390_diagnostics13193065 crossref_primary_10_3389_fonc_2019_01483 crossref_primary_10_1158_1535_7163_MCT_24_0908 crossref_primary_10_1186_s12885_024_12336_0 crossref_primary_10_1002_advs_202002365 crossref_primary_10_1016_j_cej_2021_129774 crossref_primary_10_1007_s00262_025_04007_1 crossref_primary_10_3389_fimmu_2023_1122430 crossref_primary_10_1210_jendso_bvab100 crossref_primary_10_3390_cancers14051240 crossref_primary_10_1038_s41571_021_00473_5 crossref_primary_10_1080_14737140_2022_2139240 crossref_primary_10_1186_s12885_021_09156_x crossref_primary_10_3390_cancers14051248 crossref_primary_10_3390_biomedicines10092146 crossref_primary_10_3389_fimmu_2022_1085766 crossref_primary_10_3389_fphar_2020_00722 crossref_primary_10_1038_s41416_025_02962_1 crossref_primary_10_3390_cancers13215471 crossref_primary_10_3171_CASE21373 crossref_primary_10_1002_adfm_201910676 crossref_primary_10_1186_s12967_023_04184_6 crossref_primary_10_1007_s40257_020_00506_2 crossref_primary_10_1016_j_jid_2020_02_005 crossref_primary_10_1016_j_ijrobp_2019_12_033 crossref_primary_10_3389_fonc_2023_1203470 crossref_primary_10_1097_RLU_0000000000003922 crossref_primary_10_1111_exd_14023 crossref_primary_10_1080_0284186X_2019_1620966 crossref_primary_10_1080_2162402X_2020_1731942 crossref_primary_10_1002_jso_26229 crossref_primary_10_1007_s12072_024_10688_0 crossref_primary_10_1056_NEJMoa1904059 crossref_primary_10_1158_1078_0432_CCR_22_2164 crossref_primary_10_1080_08820538_2025_2458658 crossref_primary_10_1007_s00262_020_02716_3 crossref_primary_10_1186_s12967_020_02340_w crossref_primary_10_1002_cam4_5070 crossref_primary_10_3390_cancers11030356 crossref_primary_10_3390_cancers15102856 crossref_primary_10_1007_s12272_019_01140_1 crossref_primary_10_1016_S0140_6736_20_32598_8 crossref_primary_10_1016_j_it_2018_11_003 crossref_primary_10_3390_diagnostics14060654 crossref_primary_10_1111_pcmr_13188 crossref_primary_10_3389_fimmu_2024_1255825 crossref_primary_10_1016_j_intimp_2024_111601 crossref_primary_10_3389_fimmu_2025_1616325 crossref_primary_10_3390_medsci7020014 crossref_primary_10_3389_fcell_2022_1003656 crossref_primary_10_1158_1078_0432_CCR_22_2176 crossref_primary_10_1016_j_det_2019_05_001 crossref_primary_10_1186_s12885_020_07508_7 crossref_primary_10_1016_j_jaci_2020_04_044 crossref_primary_10_1056_NEJMoa2407417 |
| Cites_doi | 10.1634/theoncologist.2010-0190 10.1200/JCO.2018.36.15_suppl.9504 10.1093/annonc/mdx642 10.1016/S0140-6736(17)31601-X 10.1200/JCO.2017.74.1025 10.1056/NEJMoa1504030 10.1056/NEJMoa1709684 10.1111/j.1365-2753.2005.00598.x 10.1200/JCO.2014.56.2736 10.1016/S1470-2045(16)30366-7 10.1200/JCO.2017.35.15_suppl.9526 10.1111/j.0006-341X.2000.00337.x 10.1200/JCO.2018.36.15_suppl.9503 10.1093/annonc/mdx176 10.1200/JCO.2017.73.2289 10.1200/JCO.2014.59.4358 10.1093/annonc/mdx339 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier Ltd Elsevier Ltd Copyright © 2018 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Nov 2018 |
| Copyright_xml | – notice: 2018 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2018 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Nov 2018 |
| DBID | AAYXX CITATION NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(18)30700-9 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1492 |
| ExternalDocumentID | 30361170 10_1016_S1470_2045_18_30700_9 S1470204518307009 1_s2_0_S1470204518307009 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Bristol-Myers Squibb. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c502t-c81b773aa06945df4171a4dd5f6bf37e491a3d82c5c1b24525cc2895881f2d9d3 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 1114 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000449100300045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Sun Sep 28 08:25:29 EDT 2025 Tue Oct 07 05:41:04 EDT 2025 Wed Feb 19 02:36:37 EST 2025 Sat Nov 29 07:04:27 EST 2025 Tue Nov 18 22:15:18 EST 2025 Fri Feb 23 02:31:13 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Oct 14 19:35:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | Copyright © 2018 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-c81b773aa06945df4171a4dd5f6bf37e491a3d82c5c1b24525cc2895881f2d9d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 30361170 |
| PQID | 2127625999 |
| PQPubID | 46089 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2126906785 proquest_journals_2127625999 pubmed_primary_30361170 crossref_citationtrail_10_1016_S1470_2045_18_30700_9 crossref_primary_10_1016_S1470_2045_18_30700_9 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30700_9 elsevier_clinicalkeyesjournals_1_s2_0_S1470204518307009 elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30700_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-11-01 |
| PublicationDateYYYYMMDD | 2018-11-01 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2018 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Long, Schachter, Ribas (bib8) 2018; 36 Garbe, Eigentler, Keilholz, Hauschild, Kirkwood (bib1) 2011; 16 Chapman, Robert, Larkin (bib4) 2017; 28 Linden (bib14) 2006; 12 Heagerty, Lumley, Pepe (bib15) 2000; 56 Schadendorf, Wolchok, Hodi (bib12) 2017; 35 Long, Flaherty, Stroyakovskiy (bib9) 2017; 28 Chapman, Ascierto, Schadendorf (bib3) 2017; 35 Schadendorf, Hodi, Robert (bib2) 2015; 33 Schachter, Ribas, Long (bib7) 2017; 390 Dummer, Ascierto, Gogas (bib10) 2018; 36 Larkin, Chiarion-Sileni, Gonzalez (bib13) 2015; 373 Postow, Callahan, Wolchok (bib5) 2015; 33 Wolchok, Chiarion-Sileni, Gonzalez (bib6) 2017; 377 Long, Eroglu, Infante (bib16) 2018; 36 Pollack, Betof, Dearden (bib17) 2018; 29 Hodi, Chesney, Pavlick (bib11) 2016; 17 Linden (10.1016/S1470-2045(18)30700-9_bib14) 2006; 12 Garbe (10.1016/S1470-2045(18)30700-9_bib1) 2011; 16 Schadendorf (10.1016/S1470-2045(18)30700-9_bib12) 2017; 35 Pollack (10.1016/S1470-2045(18)30700-9_bib17) 2018; 29 Long (10.1016/S1470-2045(18)30700-9_bib9) 2017; 28 Larkin (10.1016/S1470-2045(18)30700-9_bib13) 2015; 373 Heagerty (10.1016/S1470-2045(18)30700-9_bib15) 2000; 56 Schadendorf (10.1016/S1470-2045(18)30700-9_bib2) 2015; 33 Chapman (10.1016/S1470-2045(18)30700-9_bib3) 2017; 35 Long (10.1016/S1470-2045(18)30700-9_bib8) 2018; 36 Postow (10.1016/S1470-2045(18)30700-9_bib5) 2015; 33 Schachter (10.1016/S1470-2045(18)30700-9_bib7) 2017; 390 Long (10.1016/S1470-2045(18)30700-9_bib16) 2018; 36 Hodi (10.1016/S1470-2045(18)30700-9_bib11) 2016; 17 Chapman (10.1016/S1470-2045(18)30700-9_bib4) 2017; 28 Dummer (10.1016/S1470-2045(18)30700-9_bib10) 2018; 36 Wolchok (10.1016/S1470-2045(18)30700-9_bib6) 2017; 377 30361171 - Lancet Oncol. 2018 Nov;19(11):1424-1426 30507434 - Lancet Oncol. 2018 Dec;19(12):e668 30507488 - Lancet Oncol. 2018 Nov;19(11):e581 |
| References_xml | – volume: 12 start-page: 132 year: 2006 end-page: 139 ident: bib14 article-title: Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis publication-title: J Eval Clin Pract – volume: 33 start-page: 1974 year: 2015 end-page: 1982 ident: bib5 article-title: Immune checkpoint blockade in cancer therapy publication-title: J Clin Oncol – volume: 377 start-page: 1345 year: 2017 end-page: 1356 ident: bib6 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med – volume: 33 start-page: 1889 year: 2015 end-page: 1894 ident: bib2 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J Clin Oncol – volume: 36 start-page: 9503 year: 2018 ident: bib8 article-title: 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2 years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006 publication-title: J Clin Oncol – volume: 28 start-page: 1631 year: 2017 end-page: 1639 ident: bib9 article-title: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study publication-title: Ann Oncol – volume: 36 start-page: 9504 year: 2018 ident: bib10 article-title: Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in publication-title: J Clin Oncol – volume: 390 start-page: 1853 year: 2017 end-page: 1862 ident: bib7 article-title: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) publication-title: Lancet – volume: 35 start-page: 9526 year: 2017 ident: bib3 article-title: Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with publication-title: J Clin Oncol – volume: 373 start-page: 23 year: 2015 end-page: 34 ident: bib13 article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N Engl J Med – volume: 36 start-page: 667 year: 2018 end-page: 673 ident: bib16 article-title: Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib publication-title: J Clin Oncol – volume: 35 start-page: 3807 year: 2017 end-page: 3814 ident: bib12 article-title: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials publication-title: J Clin Oncol – volume: 16 start-page: 5 year: 2011 end-page: 24 ident: bib1 article-title: Systematic review of medical treatment in melanoma: current status and future prospects publication-title: Oncologist – volume: 28 start-page: 2581 year: 2017 end-page: 2587 ident: bib4 article-title: Vemurafenib in patients with BRAF publication-title: Ann Oncol – volume: 56 start-page: 337 year: 2000 end-page: 344 ident: bib15 article-title: Time-dependent ROC curves for censored survival data and a diagnostic marker publication-title: Biometrics – volume: 17 start-page: 1558 year: 2016 end-page: 1568 ident: bib11 article-title: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomized, controlled, phase 2 trial publication-title: Lancet Oncol – volume: 29 start-page: 250 year: 2018 end-page: 255 ident: bib17 article-title: Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma publication-title: Ann Oncol – volume: 16 start-page: 5 year: 2011 ident: 10.1016/S1470-2045(18)30700-9_bib1 article-title: Systematic review of medical treatment in melanoma: current status and future prospects publication-title: Oncologist doi: 10.1634/theoncologist.2010-0190 – volume: 36 start-page: 9504 issue: suppl 15 year: 2018 ident: 10.1016/S1470-2045(18)30700-9_bib10 article-title: Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.9504 – volume: 29 start-page: 250 year: 2018 ident: 10.1016/S1470-2045(18)30700-9_bib17 article-title: Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma publication-title: Ann Oncol doi: 10.1093/annonc/mdx642 – volume: 390 start-page: 1853 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib7 article-title: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) publication-title: Lancet doi: 10.1016/S0140-6736(17)31601-X – volume: 36 start-page: 667 year: 2018 ident: 10.1016/S1470-2045(18)30700-9_bib16 article-title: Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.1025 – volume: 373 start-page: 23 year: 2015 ident: 10.1016/S1470-2045(18)30700-9_bib13 article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1504030 – volume: 377 start-page: 1345 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib6 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1709684 – volume: 12 start-page: 132 year: 2006 ident: 10.1016/S1470-2045(18)30700-9_bib14 article-title: Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis publication-title: J Eval Clin Pract doi: 10.1111/j.1365-2753.2005.00598.x – volume: 33 start-page: 1889 year: 2015 ident: 10.1016/S1470-2045(18)30700-9_bib2 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2736 – volume: 17 start-page: 1558 year: 2016 ident: 10.1016/S1470-2045(18)30700-9_bib11 article-title: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomized, controlled, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30366-7 – volume: 35 start-page: 9526 issue: suppl 15 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib3 article-title: Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAFV600-mutant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.9526 – volume: 56 start-page: 337 year: 2000 ident: 10.1016/S1470-2045(18)30700-9_bib15 article-title: Time-dependent ROC curves for censored survival data and a diagnostic marker publication-title: Biometrics doi: 10.1111/j.0006-341X.2000.00337.x – volume: 36 start-page: 9503 issue: suppl year: 2018 ident: 10.1016/S1470-2045(18)30700-9_bib8 article-title: 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2 years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.9503 – volume: 28 start-page: 1631 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib9 article-title: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study publication-title: Ann Oncol doi: 10.1093/annonc/mdx176 – volume: 35 start-page: 3807 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib12 article-title: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.2289 – volume: 33 start-page: 1974 year: 2015 ident: 10.1016/S1470-2045(18)30700-9_bib5 article-title: Immune checkpoint blockade in cancer therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2014.59.4358 – volume: 28 start-page: 2581 year: 2017 ident: 10.1016/S1470-2045(18)30700-9_bib4 article-title: Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study publication-title: Ann Oncol doi: 10.1093/annonc/mdx339 – reference: 30507434 - Lancet Oncol. 2018 Dec;19(12):e668 – reference: 30361171 - Lancet Oncol. 2018 Nov;19(11):1424-1426 – reference: 30507488 - Lancet Oncol. 2018 Nov;19(11):e581 |
| SSID | ssj0017105 |
| Score | 2.7144616 |
| Snippet | Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and... SummaryBackgroundPreviously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free... Summary Background Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1480 |
| SubjectTerms | Cardiomyopathy Colitis Colon Diarrhea Hematology, Oncology, and Palliative Medicine Immunotherapy Intravenous administration Lipase Liver Melanoma Metastases Metastasis Monoclonal antibodies Motivation Mutation Neutropenia Oncology Patients PD-L1 protein Regulatory approval Studies Survival Targeted cancer therapy |
| Title | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518307009 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204518307009 https://dx.doi.org/10.1016/S1470-2045(18)30700-9 https://www.ncbi.nlm.nih.gov/pubmed/30361170 https://www.proquest.com/docview/2127625999 https://www.proquest.com/docview/2126906785 |
| Volume | 19 |
| WOSCitedRecordID | wos000449100300045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoi1AvvKELZWUkDq1U0zhx1jYXBKtWXLqqykN7sxzbUSOyybLZReIP8TvxOI8KiVIkLpHy-JI4M575Yo9nEHrFWGwtk5zwPLKEGW2J5swRbjPtXJJnzGSh2ASfzcR8Ls-7AbemC6vsbWIw1LY2MEZ-DJnIgatL-Xb5jUDVKJhd7UpobKEdGkcMOqaYDiEelLchjJTxiEDa9asVPMcfh4MHVByC4kdEXuebruOewQed3vvft7-P7nbsE79r1eUBuuWqh-jOWTe__gj9nBXBXOkML8tNg4tlURaLsF-vcDWc1GVdOQwRHb9f1B4vKtyHFuCFK3VVLzQ-mF468_XMU1vsXdfhG8zID9_LcL1Z-ya4Btc51jjEN4aAUXeEvRu1tddDZ4_w8tK7W5zgUGXkMfp8evJp-oF0lRyISaN4TYwnx5wnWsMy29TmzItGM2vTfJLlCXdMUp1YEZvU0AzmglNj_J9gKgTNYytt8gRtV74BewgnmaecTqTSWsOSfCJcLgVNjaUupkaLEWK9DJXp0pxDtY1SDfFsIHoFoldUqCB6JUfo9QBbtnk-bgJMegVR_SJWb3aV90Q3AfmfgK7pjEejqGpiFbVoAHurC1CPFAOy40ct7_mXh-73eqmG51wp5Qi9HE57scKcka5cvQnXQCprLtIRetrq_vB9gP1A4aJnf7_5c7TrWaZoF3Duo-31auNeoNvm-7poVmO0xS--wHbOw1aMQx8eo533J7Pzi1_9l0eW |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQcCFfRkoYCSQWqmmceKMHSSE0EDVqp0REq3Um3FsR43IJMNkBtQ_xJHfiJ-zVEiUcumBYxw_R3l5y-f4LQi9YCw0hiWc8CwwhGlliOLMEm5SZW2UpUynvtkEn0zE0VHycQX97HJhIKyys4neUJtKwz_yLahEDlg9Sd7OvhLoGgWnq10LjUYs9uzJd7dlq9_svnff92UYbn84GO2QtqsA0XEQLoh2QI3zSClI-YxNxiinihkTZ8M0i7hlCVWREaGONU3hXDLW2u1KYiFoFprERG7dS-gyVLKDzZ4Y9SElbiEfMkkZDwiUeT_NGNr61A-uU7EBihaQ5CxfeBbW9T5v--b_xq1b6EaLrvG7Rh1uoxVb3kFXx238wF30Y5J7c6xSPCuWNc5neZFP_XU1x2V_UxVVaTFErPw-qRnPS9yFTuCpLVRZTRVeHx1b_WXsoDt2rnnjNWbkxDEAV8uFY5mtcZVhhX38pg-ItZvYwQRTOT2zZhPPjh2cwBH2XVTuocML4dJ9tFq6F3iIcJQ6SG1FnBijWZQNhc0SQWNtqA2pVmKAWCczUrdl3KGbSCH7eD0QNQmiJqmQXtRkMkCverJZU8fkPIJhJ5CyS9J1bkU6T3seIf8Toa1b41hLKutQBg01EDuvAqSOUvSULf5rcN2_PHSt0wPZP-dUCQboeX_bfVY4E1OlrZZ-DpTq5iIeoAeNrvX8AXQHjZke_X3xZ-jazsF4X-7vTvYeo-sOUYsmWXUNrS7mS_sEXdHfFnk9f-qtBUafL1rhfgGn_J9L |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-FAUYCaZNmWidO7SAhhDoqprFqEiDtzTi2o0WkSWha0P4QP4Jfx7FzmZAY42UPPDbJcdSTc_kSf-cchJ4xFhjDYk54OjKEaWWI4swSbhJlbZgmTCd-2ASfzcTRUXy4hn52tTCOVtnFRB-oTandN_Kh60TusHocD9OWFnG4O31dfSVugpTbae3GaTQmsm9PvsPrW_1qbxee9fMgmL79OHlH2gkDREejYEk0gDbOQ6Vc-WdkUkY5VcyYKB0nacgti6kKjQh0pGni9igjreENJRKCpoGJTQjrXkKXeQhW7KrUJz29BBby9EnK-Ii4lu-n1UPDD_3BLSq2ndONSHxWXjwL9_r8N73-P2vuBrrWom78pnGTm2jNFrfQxkHLK7iNfswyH6ZVgqt8VeOsyvJs7n-XC1z0J1VeFhY7JsvvFzXHswJ3lAo8t7kqyrnCW5Njq78cAKTHkLK3X2JGTkABuFwtQX22xmWKFfa8Tk-UtTsY4IMpwf-s2cHVMcAMHGI_XeUO-nQhWrqL1gv4A_cRDhOA2lZEsTGahelY2DQWNNKG2oBqJQaIdfYjddve3U0ZyWXP43NmJ53ZSSqkNzsZD9CLXqxq-pucJzDujFN2xbuQbiRk4PME-Z8Ebd0GzVpSWQdy1Eg7Ycg2ThQkRS_Z4sIG7_3LTTc7n5D9fU4dYoCe9qfhsbq9MlXYcuWvcS28uYgG6F7jd71-HOpzA5se_H3xJ2gD_Ey-35vtP0RXAWiLpoZ1E60vFyv7CF3R35ZZvXjsAwdGny_a334BYY2oEA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab+plus+ipilimumab+or+nivolumab+alone+versus+ipilimumab+alone+in+advanced+melanoma+%28CheckMate+067%29%3A+4-year+outcomes+of+a+multicentre%2C+randomised%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Hodi%2C+Frank+Stephen&rft.au=Chiarion-Sileni%2C+Vanna&rft.au=Gonzalez%2C+Rene&rft.au=Grob%2C+Jean-Jacques&rft.date=2018-11-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.volume=19&rft.issue=11&rft.spage=1480&rft.epage=1492&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930700-9&rft.externalDocID=S1470204518307009 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204518X00114%2Fcov150h.gif |